{"id":"pld","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Palmar-plantar erythrodysesthesia (hand-foot syndrome)"},{"rate":"20-40","effect":"Nausea and vomiting"},{"rate":"10-30","effect":"Stomatitis"},{"rate":"20-40","effect":"Myelosuppression"},{"rate":"5-15","effect":"Alopecia"},{"rate":"<5","effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":{"setId":"55dba434-9a73-4693-96b2-0074b2add069","title":"EXEGEN LDLR MINISWINE (PLDLR-NEO) NOT APPLICABLE [EXEMPLAR GENETICS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug encapsulates doxorubicin in pegylated liposomes, which preferentially accumulate in tumor tissue through the enhanced permeability and retention (EPR) effect. This formulation reduces cardiotoxicity and other systemic side effects associated with free doxorubicin while preserving its DNA intercalation and topoisomerase II inhibition mechanisms. The pegylation extends circulation time and improves tumor targeting.","oneSentence":"PLD is a pegylated liposomal doxorubicin that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to reduce systemic toxicity while maintaining anti-tumor efficacy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:49.018Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Breast cancer"},{"name":"Multiple myeloma"},{"name":"Kaposi sarcoma"}]},"trialDetails":[{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT05210374","phase":"PHASE1","title":"Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2023-03-09","conditions":"Relapsed Sarcomas","enrollment":24},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":"Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":54},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT04729387","phase":"PHASE3","title":"Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-22","conditions":"Ovarian Cancer","enrollment":358},{"nctId":"NCT07109414","phase":"PHASE2, PHASE3","title":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novita Pharmaceuticals, Inc.","startDate":"2025-12-29","conditions":"Platinum-resistant Ovarian Cancer","enrollment":380},{"nctId":"NCT05467670","phase":"PHASE2","title":"Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2023-03-30","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT06619236","phase":"PHASE3","title":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2025-02-07","conditions":"Platinum-resistant Ovarian Cancer","enrollment":530},{"nctId":"NCT06787612","phase":"PHASE2","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-05-28","conditions":"Ovarian Cancer","enrollment":220},{"nctId":"NCT07395492","phase":"NA","title":"App-Based Education and Low-Residue Diet for Colonoscopy Preparation","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2026-03-01","conditions":"Bowel Preparation Solution","enrollment":420},{"nctId":"NCT05411237","phase":"PHASE3","title":"Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2026-09","conditions":"Kaposi Sarcoma, HIV-1-infection, AIDS-related Kaposi Sarcoma","enrollment":130},{"nctId":"NCT06981637","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2025-12-31","conditions":"Advanced Soft Tissue Sarcoma","enrollment":81},{"nctId":"NCT07218809","phase":"PHASE3","title":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-29","conditions":"Epithelial Ovarian Cancer","enrollment":1100},{"nctId":"NCT07340164","phase":"PHASE2","title":"Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-12-30","conditions":"Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent","enrollment":116},{"nctId":"NCT06161025","phase":"PHASE2, PHASE3","title":"A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-27","conditions":"Solid Cancer","enrollment":860},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":"Lymphoma, Follicular","enrollment":90},{"nctId":"NCT06849986","phase":"PHASE2","title":"IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-25","conditions":"Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma","enrollment":45},{"nctId":"NCT05483933","phase":"PHASE1","title":"Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers","status":"COMPLETED","sponsor":"Shattuck Labs, Inc.","startDate":"2022-08-18","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT05281328","phase":"PHASE2, PHASE3","title":"A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2022-06-28","conditions":"Polycystic Liver Disease","enrollment":71},{"nctId":"NCT07037446","phase":"","title":"A Multicenter, International, Prospective and Retrospective, Follow-up Registry to Monitor the Efficacy and Safety of the Occlutech Paravalvular Leak Device (PLD) in Patients With Mitral or Aortic Paravalvular Leaks","status":"ENROLLING_BY_INVITATION","sponsor":"Occlutech International AB","startDate":"2025-02-05","conditions":"Paravalvular Leak Device (PLD)","enrollment":200},{"nctId":"NCT02101788","phase":"PHASE2, PHASE3","title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-11","conditions":"Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma","enrollment":260},{"nctId":"NCT05271318","phase":"PHASE1, PHASE2","title":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.","status":"RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2022-05-17","conditions":"Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma","enrollment":29},{"nctId":"NCT05613088","phase":"PHASE2","title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-02-01","conditions":"Neoplasms, Ovarian","enrollment":106},{"nctId":"NCT05870748","phase":"PHASE2, PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":600},{"nctId":"NCT05092360","phase":"PHASE3","title":"Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)","status":"TERMINATED","sponsor":"Mural Oncology, Inc","startDate":"2022-01-10","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":456},{"nctId":"NCT05029999","phase":"PHASE1","title":"CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-04-20","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer","enrollment":30},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT05830539","phase":"PHASE1, PHASE2","title":"IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients","status":"COMPLETED","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-03-10","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":68},{"nctId":"NCT05551507","phase":"PHASE1, PHASE2","title":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2020-07-27","conditions":"Platinum-resistant Ovarian Cancer","enrollment":150},{"nctId":"NCT06014528","phase":"PHASE2","title":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-09-06","conditions":"Ovarian Cancer Recurrent","enrollment":168},{"nctId":"NCT04274426","phase":"PHASE2","title":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AGO Research GmbH","startDate":"2021-10-13","conditions":"Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma","enrollment":136},{"nctId":"NCT03353831","phase":"PHASE3","title":"Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer","status":"COMPLETED","sponsor":"AGO Research GmbH","startDate":"2018-09-11","conditions":"Recurrent Ovarian Carcinoma","enrollment":574},{"nctId":"NCT02641639","phase":"PHASE2, PHASE3","title":"FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer","status":"TERMINATED","sponsor":"Mateon Therapeutics","startDate":"2016-06","conditions":"Platinum Resistant Ovarian Cancer","enrollment":70},{"nctId":"NCT03164980","phase":"PHASE4","title":"QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2018-02-01","conditions":"Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma","enrollment":89},{"nctId":"NCT02098343","phase":"PHASE1, PHASE2","title":"p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2014-03","conditions":"Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53","enrollment":247},{"nctId":"NCT03268382","phase":"PHASE2","title":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2017-07-31","conditions":"High-grade Serous Ovarian Cancer","enrollment":36},{"nctId":"NCT04421547","phase":"PHASE3","title":"Efficacy of Letrozole in Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-06-22","conditions":"Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT06687070","phase":"PHASE1","title":"APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-12-17","conditions":"Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor","enrollment":50},{"nctId":"NCT01314105","phase":"PHASE1","title":"BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-03-15","conditions":"Ovarian Neoplasms, Peritoneal Neoplasms","enrollment":19},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT00170573","phase":"PHASE2","title":"Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer","status":"COMPLETED","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2001-09","conditions":"Ovarian Cancer","enrollment":77},{"nctId":"NCT04516447","phase":"PHASE1","title":"A Study of ZN-c3 in Patients With Ovarian Cancer","status":"RECRUITING","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","startDate":"2020-10-26","conditions":"Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":140},{"nctId":"NCT05261490","phase":"PHASE1, PHASE2","title":"Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-08-01","conditions":"Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma","enrollment":10},{"nctId":"NCT05257018","phase":"PHASE2","title":"R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-02-26","conditions":"Diffuse Large B-cell Lymphoma","enrollment":83},{"nctId":"NCT06653972","phase":"PHASE2","title":"Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Wang Jiayu","startDate":"2024-11-01","conditions":"Her2-negative Metastatic Breast Cancer, Vinorelbine, Liposomal Doxorubicin","enrollment":30},{"nctId":"NCT03596281","phase":"PHASE1","title":"Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-12-05","conditions":"Ovarian Cancer","enrollment":47},{"nctId":"NCT02173080","phase":"","title":"Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-06","conditions":"Polycystic Liver Disease","enrollment":594},{"nctId":"NCT03598270","phase":"PHASE3","title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2018-11-21","conditions":"Recurrent Ovarian Carcinoma","enrollment":417},{"nctId":"NCT01696032","phase":"PHASE2","title":"SGI-110 in Combination With Carboplatin in Ovarian Cancer","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2012-09","conditions":"Ovarian Cancer","enrollment":120},{"nctId":"NCT03719326","phase":"PHASE1","title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","status":"COMPLETED","sponsor":"Arcus Biosciences, Inc.","startDate":"2018-10-15","conditions":"TNBC - Triple-Negative Breast Cancer, Ovarian Cancer","enrollment":35},{"nctId":"NCT01279291","phase":"PHASE1","title":"Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer","status":"TERMINATED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2011-01","conditions":"Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms","enrollment":22},{"nctId":"NCT03907969","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-10-09","conditions":"Advanced Malignancies","enrollment":30},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT04244552","phase":"PHASE1","title":"A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies","status":"TERMINATED","sponsor":"Atreca, Inc.","startDate":"2020-02-11","conditions":"Breast Cancer, Colorectal Cancer, Ovarian Cancer","enrollment":87},{"nctId":"NCT04877275","phase":"PHASE2","title":"ATG-010(Selinexor) in Combination With Chemotherapy in RRMM","status":"UNKNOWN","sponsor":"Chunyan Sun, MD","startDate":"2021-05-21","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT02584478","phase":"PHASE3","title":"Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)","status":"UNKNOWN","sponsor":"Advenchen Laboratories, LLC","startDate":"2015-12","conditions":"Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma","enrollment":294},{"nctId":"NCT02188368","phase":"PHASE2","title":"Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-07-07","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT02272790","phase":"PHASE2","title":"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-30","conditions":"Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation","enrollment":95},{"nctId":"NCT05201001","phase":"PHASE2","title":"APX005M in Patients With Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2023-09-07","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT05976932","phase":"","title":"Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-08","conditions":"Ovarian Cancer","enrollment":20},{"nctId":"NCT02580058","phase":"PHASE3","title":"A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-12-21","conditions":"Ovarian Cancer","enrollment":566},{"nctId":"NCT05868889","phase":"","title":"Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2021-10-21","conditions":"Ovarian Cancer","enrollment":43},{"nctId":"NCT05407584","phase":"PHASE2","title":"Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2022-07-05","conditions":"PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment","enrollment":56},{"nctId":"NCT05844813","phase":"PHASE4","title":"Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma","status":"ENROLLING_BY_INVITATION","sponsor":"Peking University International Hospital","startDate":"2022-11-01","conditions":"Retroperitoneal Sarcoma","enrollment":102},{"nctId":"NCT05141123","phase":"","title":"Registry of Patients Treated by Preloaded Fenestrated Stent-graft Designs for Complex Endovascular Aortic Procedures","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2022-10-30","conditions":"Renal Aneurysm, Aneurysm Thoracic, Aneurysm Abdominal","enrollment":741},{"nctId":"NCT05255471","phase":"PHASE3","title":"MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2022-01-21","conditions":"Ovarian Cancer","enrollment":200},{"nctId":"NCT01802749","phase":"PHASE3","title":"Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2013-11","conditions":"Recurrent Ovarian Cancer","enrollment":406},{"nctId":"NCT05536102","phase":"PHASE2","title":"The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-09-05","conditions":"Gastric Cancer","enrollment":38},{"nctId":"NCT00128778","phase":"PHASE4","title":"Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2002-10-28","conditions":"Breast Neoplasms","enrollment":288},{"nctId":"NCT05386524","phase":"PHASE2","title":"Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-06-15","conditions":"Breast Cancer","enrollment":41},{"nctId":"NCT05731258","phase":"","title":"Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Liposomal Doxorubicin, Efficacy","enrollment":150},{"nctId":"NCT03639246","phase":"PHASE1","title":"Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Aravive, Inc.","startDate":"2018-12-06","conditions":"Ovarian Cancer","enrollment":53},{"nctId":"NCT03161132","phase":"PHASE2","title":"Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2017-12-13","conditions":"Advanced Ovarian Cancer","enrollment":32},{"nctId":"NCT03302130","phase":"NA","title":"The Effects of Mood on Cerebral Perfusion","status":"COMPLETED","sponsor":"University Ghent","startDate":"2016-01-08","conditions":"Cerebral Perfusion","enrollment":48},{"nctId":"NCT02431559","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2015-12-02","conditions":"Ovarian Cancer","enrollment":53},{"nctId":"NCT02865811","phase":"PHASE2","title":"Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-09-15","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":26},{"nctId":"NCT05512676","phase":"","title":"Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2016-03-07","conditions":"Ovarian Neoplasm, Chemotherapeutic Toxicity, Chemotherapy Effect","enrollment":40},{"nctId":"NCT03794778","phase":"PHASE4","title":"Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer","status":"UNKNOWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2019-03-19","conditions":"Efficacy and Safety","enrollment":396},{"nctId":"NCT00976911","phase":"PHASE3","title":"AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-29","conditions":"Ovarian Cancer","enrollment":361},{"nctId":"NCT05346107","phase":"PHASE2","title":"PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2020-01-01","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":100},{"nctId":"NCT03003481","phase":"","title":"Follow-up Registry to Monitor the Efficacy and Safety of the Occlutech PLD Device","status":"COMPLETED","sponsor":"Occlutech International AB","startDate":"2016-10","conditions":"Mitral Paravalvular Leaks (PVL), Aortic Paravalvular Leaks (PVL)","enrollment":144},{"nctId":"NCT03071926","phase":"PHASE2","title":"Metronomic PLD in Patients With Primary Endocrine Resistant ABC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2017-03-01","conditions":"Advanced Breast Cancer","enrollment":46},{"nctId":"NCT00785798","phase":"PHASE1, PHASE2","title":"Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas","status":"TERMINATED","sponsor":"Yale University","startDate":"2009-01","conditions":"Relapsed Lymphomas, Refractory Lymphomas","enrollment":17},{"nctId":"NCT04348032","phase":"PHASE2","title":"Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-03-22","conditions":"Platinum-resistant Recurrent Ovarian Cancer","enrollment":152},{"nctId":"NCT03690739","phase":"PHASE3","title":"Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"AGO Research GmbH","startDate":"2019-08-09","conditions":"Recurrent Ovarian Carcinoma","enrollment":9},{"nctId":"NCT01379989","phase":"PHASE3","title":"INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2011-06","conditions":"Ovarian Cancer","enrollment":617},{"nctId":"NCT04620954","phase":"PHASE1, PHASE2","title":"Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2020-10-07","conditions":"Epithelial Ovarian Cancer","enrollment":31},{"nctId":"NCT02825420","phase":"","title":"Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients","status":"COMPLETED","sponsor":"PharmaMar","startDate":"2015-07-28","conditions":"Relapsed Ovarian Cancer","enrollment":220},{"nctId":"NCT05097248","phase":"PHASE2","title":"Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-10","conditions":"Breast Cancer","enrollment":52},{"nctId":"NCT01170650","phase":"PHASE3","title":"Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)","status":"TERMINATED","sponsor":"Endocyte","startDate":"2011-04-22","conditions":"Ovarian Cancer","enrollment":441},{"nctId":"NCT02289950","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2015-03-19","conditions":"Platinum-Sensitive Ovarian Cancer in First Relapse","enrollment":332},{"nctId":"NCT04887961","phase":"PHASE2","title":"Reprab Study: PLD + Trabectedin Rechallenge","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-10-01","conditions":"Relapsed Ovarian Cancer","enrollment":64},{"nctId":"NCT04983550","phase":"PHASE2","title":"Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-09","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":126},{"nctId":"NCT01837251","phase":"PHASE3","title":"Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"AGO Research GmbH","startDate":"2013-05","conditions":"Recurrent Platinum-sensitive Ovarian Cancer","enrollment":682},{"nctId":"NCT03699449","phase":"PHASE2","title":"An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2018-11-26","conditions":"Platinum-resistant Recurrent Ovarian Cancer","enrollment":104},{"nctId":"NCT01736943","phase":"PHASE2","title":"Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"Joseph Tuscano","startDate":"2012-12-19","conditions":"Acute Myelogenous Leukemia","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6556,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["doxorubicin, caelyx","duomeisu","DOXIL, Caelyx","ATI-0918","doxorubicin hydrochloride liposome"],"phase":"marketed","status":"active","brandName":"PLD","genericName":"PLD","companyName":"AGO Research GmbH","companyId":"ago-research-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PLD is a pegylated liposomal doxorubicin that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to reduce systemic toxicity while maintaining anti-tumor efficacy. Used for Ovarian cancer, Breast cancer, Multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}